Atiprimod (azaspirane, SK&F106615)
Updated: Nov 14, 2009
| Brand Name: | Atiprimod |
| Generic Name: | azaspirane |
| Code Name: | SK&F106615 |
| Company: | Callisto Pharmaceuticals |
| FDA Clinical Phase: | 1/2 |
Description:
Atiprimod is a type of signal transduction inhibitor. It is being studied in the treatment of certain multiple myelomas and other advanced cancers. Atiprimod may block the growth of tumors and the growth of new blood vessels that tumors need to grow.
Clinical Trials:
For a list of clinical trials studying Atiprimod for the treatment of multiple myeloma, see ClinicalTrials.gov.
Source: NCI Cancer Glossary, Atiprimod, http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod (as of November 14, 2009)
Related Articles:
- Getting To Know: Tiragolumab
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
- Getting To Know: TNB-383B
